Ophthalmology wRVU Compensation in 2026: Benchmarks, Cataract Volume, ASC Income, and What to Ask Before You Sign

Ophthalmology compensation is one of the most variable in medicine. The base wRVU compensation is meaningful — $55/wRVU at 8,500 wRVUs annually — but the real income leverage comes from cataract surgery volume, ambulatory surgery center ownership, and optical (eyewear) revenue split. A cataract surgeon with ASC ownership in a high-volume practice can earn 2-3x what a comparable surgeon without those revenue streams earns. Contract terms governing these layers determine the actual financial structure of an ophthalmology job.

If you are an ophthalmologist evaluating a contract — finishing residency or fellowship, switching practices, or considering a private group versus corporate ophthalmology platform — here is what the 2026 market actually looks like and where the financial leverage lives.

What the 2026 ophthalmology benchmarks actually are

Based on MGMA 2025 data, the median ophthalmologist produces approximately 8,500 wRVUs annually at $55 per wRVU. Total compensation at the median runs $430,000-$475,000 in clinical-only practices. Ophthalmologists in practices with ASC ownership and high cataract volume routinely exceed $700,000-$900,000.

The 75th percentile ophthalmologist produces around 10,500 wRVUs annually. The 90th percentile is 13,000 — typically reflecting either a high-volume cataract practice or a subspecialty (retina, glaucoma, oculoplastics) with substantial procedural billing.

Ophthalmology is meaningfully affected by the 2026 CMS efficiency adjustment. Cataract surgery, intravitreal injections, laser procedures, and most other ophthalmologic procedures carry slightly reduced wRVU values in 2026 versus 2025.

The three ophthalmology contract traps

ASC ownership terms with vesting periods longer than typical contract length. This is the biggest financial issue in ophthalmology contracts. Many ophthalmology practices offer ambulatory surgery center ownership opportunities. These can be enormous — a meaningful stake in a high-volume cataract ASC can generate $300,000-$800,000 annually in distributions. But vesting terms often extend 5-7 years, and many contracts include language allowing the ASC to repurchase your stake at book value if you leave before vesting completes.

Book value of an ASC stake is typically a small fraction of fair market value. If you sign a 3-year contract with a 5-year ASC vesting schedule, you have created an automatic financial penalty for changing jobs that may not be obvious at the time of signing.

Ask for the vesting schedule, the buyout methodology if you leave before vesting, and the historical distribution amounts over the past 3-5 years.

Cataract volume targets that quietly require unsustainable case loads. Many ophthalmology contracts include language tying compensation or bonus to cataract surgery volume — '600+ cataract cases annually' or '15 cases per OR day.' These targets sound straightforward but require a specific patient referral pipeline and OR access that may not actually exist in your practice setting.

If your contract assumes 600 cataract cases annually but your practice can only deliver 400 cases worth of referrals and OR access, your bonus compensation is structurally capped. Ask for explicit language defining what referral volume and OR access the practice will actually provide.

Optical revenue split that gives the practice most of the upside. Many ophthalmology practices include optical (eyewear) services. Optical revenue can be substantial — $200,000-$600,000 annually per ophthalmologist depending on patient volume and optical conversion rates. Most contracts retain optical revenue with the practice, paying the ophthalmologist a flat percentage that is often well below what equivalent optometric or independent practices would generate.

Fair contract language addresses this — either through a transparent revenue share back to the ophthalmologist whose patients drive optical sales, or through an elevated per-wRVU rate that effectively captures a share of the practice revenue.

What fair ophthalmology contract language looks like

On the wRVU structure: a threshold at or below the 50th percentile (around 8,500 wRVUs) with a rate at or above $55/wRVU, explicitly benchmarked against 2026 (not 2025) MGMA data.

On ASC ownership: explicit vesting schedule, buyout methodology that reflects fair market value (not book value), and disclosed historical distributions over the past 3-5 years.

On cataract volume: explicit referral pipeline and OR access commitments that match the production targets in the contract.

On optical revenue: transparent revenue share back to the ophthalmologist whose patients drive optical sales.

What to ask before you sign

Four specific questions worth getting answered in writing before you commit to an ophthalmology contract:

1. If this contract includes ASC ownership opportunity, what is the vesting schedule, the buyout methodology if I leave before vesting, and the historical annual distribution amount?
2. If cataract volume targets are part of the compensation structure, what referral pipeline and OR access will the practice actually provide?
3. What happens with optical revenue, and is there a transparent revenue share back to me based on my patient panel?
4. Was the wRVU threshold benchmarked against 2025 or 2026 MGMA values, given the CMS efficiency adjustment to procedural codes including cataract surgery?

These are the questions that separate a $430,000 contract from a $900,000+ contract for an ophthalmologist with cataract volume and ASC opportunity. Vague answers on ASC vesting, cataract pipeline, or optical revenue tell you exactly how the math will work in practice.

Want to know how your specific ophthalmology contract compares to these benchmarks? FairRVU runs the full analysis in 60 seconds — wRVU threshold percentile, ASC vesting evaluation, cataract volume realism check, and optical revenue analysis. Your contract is permanently deleted after processing.